We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.84%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$372M
AUM Growth
+$4.91M
Cap. Flow
-$21.9M
Cap. Flow %
-5.89%
Top 10 Hldgs %
47.82%
Holding
97
New
8
Increased
10
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$3.96M
2
MDWD icon
MediWound
MDWD
+$2.57M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.16M
4
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.4M
5
KURA icon
Kura Oncology
KURA
+$1.37M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.71M
2
NTUS
Natus Medical Inc
NTUS
+$4.71M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.96M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.65M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPSC icon
26
Century Therapeutics
IPSC
$346M
$4.7M 1.26%
475,367
– –
RCUS icon
27
Arcus Biosciences
RCUS
$3.48B
$4.67M 1.26%
178,717
-9,000
-5% -$238K
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$4.65M 1.25%
307,232
+18,192
+6% +$211K
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
$4.5M 1.21%
65,946
-30,989
-32% -$1.83M
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
$3.98M 1.07%
286,988
– –
AXGN icon
31
Axogen
AXGN
$2.39B
$3.96M 1.06%
332,103
– –
ETNB
32
DELISTED
89bio
ETNB
$3.79M 1.02%
654,862
-111,912
-15% -$492K
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$3.71M 1%
255,313
-10,350
-4% -$145K
FSTX
34
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.95M 0.79%
576,881
– –
BCYC
35
Bicycle Therapeutics
BCYC
$277M
$2.84M 0.76%
122,200
-9,000
-7% -$214K
KURA icon
36
Kura Oncology
KURA
$833M
$2.82M 0.76%
206,329
+88,500
+75% +$1.37M
ATRC icon
37
AtriCure
ATRC
$2.05B
$2.82M 0.76%
72,029
– –
MRSN
38
DELISTED
Mersana Therapeutics
MRSN
$2.55M 0.69%
15,111
-1,160
-7% -$189K
MDWD icon
39
MediWound
MDWD
$185M
$1.99M 0.53%
+204,082
New +$2.57M
VIGL
40
DELISTED
Vigil Neuroscience
VIGL
$1.97M 0.53%
216,395
+116,641
+117% +$855K
ARAY icon
41
Accuray
ARAY
$33.8M
$1.96M 0.53%
941,800
– –
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
$1.86M 0.5%
97,560
-7,738
-7% -$178K
LRMR icon
43
Larimar Therapeutics
LRMR
$437M
$1.84M 0.49%
574,996
+525,000
+1,050% +$1.32M
LKFT
44
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.69B
$1.82M 0.49%
42,675
– –
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.71M 0.46%
+265,878
New +$2.16M
DICE
46
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$1.59M 0.43%
78,500
-78,404
-50% -$1.43M
VKTX icon
47
Viking Therapeutics
VKTX
$3.88B
$1.5M 0.4%
552,400
+90,000
+19% +$295K
KROS icon
48
Keros Therapeutics
KROS
$202M
$1.47M 0.39%
39,000
– –
AFMD
49
DELISTED
Affimed
AFMD
$1.41M 0.38%
68,628
– –
ORIC icon
50
Oric Pharmaceuticals
ORIC
$1.34B
$1.32M 0.36%
413,526
-2,400
-0.6% -$9.61K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, DAFNA Capital Management held 97 positions worth $372M, up 1.3% from $367M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $21.9M in Q3 2022, closing 10 positions and reducing 34 holdings. Its most notable exit was Natus Medical Inc, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in MediWound worth $1.99M.

  • DAFNA Capital Management's largest Q3 2022 buy was MediWound: 204,082 shares worth $1.99M.
  • DAFNA Capital Management added most to Revolution Medicines in Q3 2022, an estimated $3.96M increase.
  • DAFNA Capital Management's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $6.71M.
  • DAFNA Capital Management fully exited Natus Medical Inc in Q3 2022, selling an estimated $4.71M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $372M portfolio in Q3 2022.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q3 2022.
  • DAFNA Capital Management's portfolio value rose 1.3% quarter-over-quarter to $372M.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.